Macquarie Group LTD Neurocrine Biosciences Inc Transaction History

Macquarie Group LTD

$85.1 Billion
Q2 2024

A detailed history of Macquarie Group LTD transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Macquarie Group LTD holds 270,977 shares of NBIX stock, worth $32.1 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

270,977

Previous 276,010 1.82%

Holding current value

$32.1 Million

Previous $38.1 Million 2.0%

% of portfolio

0.04%

Previous 0.04%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$130.86 - $143.19 $658,618 - $720,675	-5,033 Reduced 1.82%	270,977 $37.3 Million
Q1 2024 May 14, 2024	SELL	$130.4 - $143.74 $6.8 Million - $7.49 Million	-52,119 Reduced 15.88%	276,010 $38.1 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $7.37 Million - $9.23 Million	69,518 Added 26.88%	328,129 $43.2 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $76,720 - $95,553	-816 Reduced 0.31%	258,611 $29.1 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $2.97 Million - $3.48 Million	-33,183 Reduced 11.34%	259,427 $24.5 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $686,626 - $897,553	7,296 Added 2.56%	292,610 $29.6 Million
Q4 2022 Feb 21, 2023	SELL	$106.72 - $127.06 $105,652 - $125,789	-990 Reduced 0.35%	285,314 $34.1 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $606,109 - $710,036	-6,586 Reduced 2.25%	286,304 $30.4 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $1.91 Million - $2.52 Million	-25,173 Reduced 7.91%	292,890 $28.6 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $4.73 Million - $6.19 Million	65,302 Added 25.84%	318,063 $29.8 Million
Q4 2021 Feb 11, 2022	BUY	$79.65 - $106.22 $1.49 Million - $1.98 Million	18,676 Added 7.98%	252,761 $21.5 Million
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $204,332 - $234,800	-2,371 Reduced 1.0%	234,085 $22.5 Million
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $688,521 - $787,376	7,699 Added 3.37%	236,456 $23 Million
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $243,707 - $332,290	-2,783 Reduced 1.2%	228,757 $22.2 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $62.5 Million - $77.8 Million	-718,601 Reduced 75.63%	231,540 $22.2 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $3.61 Million - $5.07 Million	37,532 Added 4.11%	950,141 $91.4 Million
Q2 2020 Aug 11, 2020	BUY	$85.09 - $130.36 $57.6 Million - $88.3 Million	677,365 Added 287.94%	912,609 $111 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $22,382 - $33,900	298 Added 0.13%	235,244 $20.4 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $46,524 - $63,553	536 Added 0.23%	234,946 $25.3 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $609,539 - $738,108	-7,272 Reduced 3.01%	234,410 $21.1 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $598,002 - $755,533	8,278 Added 3.55%	241,682 $20.4 Million
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $2.68 Million - $3.55 Million	-38,731 Reduced 14.23%	233,404 $20.6 Million
Q4 2018 Feb 15, 2019	SELL	$68.32 - $124.36 $31 Million - $56.4 Million	-453,627 Reduced 62.5%	272,135 $19.4 Million
Q3 2018 Nov 15, 2018	SELL	$98.88 - $125.85 $10.7 Million - $13.6 Million	-108,387 Reduced 12.99%	725,762 $89.2 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $4.74 Million - $6.68 Million	62,979 Added 8.17%	834,149 $81.9 Million
Q1 2018 May 11, 2018	BUY	$75.88 - $92.43 $4.65 Million - $5.66 Million	61,249 Added 8.63%	771,170 $64 Million
Q4 2017 Feb 15, 2018	SELL	$58.53 - $77.59 $3.12 Million - $4.14 Million	-53,311 Reduced 6.98%	709,921 $55.1 Million
Q3 2017 Nov 08, 2017	BUY	$47.97 - $61.28 $36.6 Million - $46.8 Million	763,232	763,232 $46.8 Million

Others Institutions Holding NBIX

# of Institutions

641

Shares Held

95.3M

Call Options Held

661K

Put Options Held

227K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.3B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Neurocrine Biosciences Inc Transaction History